Celcuity (CELC) stock: gedatolisib Phase 3 VIKTORIA-1 PFS gains in HR+/HER2- breast cancer, runway to 2027 and valuation ...
The influence of margin width and volume of disease near margin on benefit of radiation therapy after breast-conserving surgery for DCIS: Results of long-term follow-up No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results